Pharmacokinetics and Bioequivalence of Two Formulations of Apixaban Tablets: A Double-Blind, Single-Dose, Crossover Study in Healthy Subjects
The test product (apixaban 5 mg tablet) and reference product (Eliquis<sup>®</sup>) achieved regulatory requirements for bioequivalence in healthy individuals under a fasted state.
Authors
- Erfan Abdollahizad
- Mohammad Reza Afshar Mogaddam (ORCID: https://orcid.org/0000-0003-1144-4523)
- Azadeh Haeri (ORCID: https://orcid.org/0000-0003-2234-9222)
- Zahra Abbasian (ORCID: https://orcid.org/0000-0003-4331-0343)
- Simin Dadashzadeh (ORCID: https://orcid.org/0000-0003-1420-8796)
- Abolghasem Jouyban (ORCID: https://orcid.org/0000-0002-4670-2783)
Institutions
- Tabriz University of Medical Sciences (IR)
- Mersin Üniversitesi (TR)
- Shahid Beheshti University of Medical Sciences (IR)
- Near East University (CY)
Publication Details
- Journal
- Iranian journal of pharmaceutical research
- Published
- 2025-04-03
- DOI
- https://doi.org/10.5812/ijpr-157714
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00